NESS ZIONA, Israel, Sept. 13,
2017 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq:
BVXV, TASE: BVXV), a clinical stage biopharmaceutical company
focused on developing and commercializing M-001, a universal flu
vaccine candidate, announced today that it has priced an
underwritten public offering of 1,500,000 American Depositary
Shares ("ADS"), each ADS representing forty (40) of its ordinary
shares which are listed on the Tel Aviv Stock Exchange (at
NIS 0.0000001 par value each), at a
price to the public of $6.00 per
ADS.
BiondVax Pharmaceuticals has granted the underwriter a 45-day
option to purchase up to 166,667 additional ADS. The offering is
expected to close on or about September 18,
2017, subject to satisfaction of customary closing
conditions.
Dr. Ron Babecoff,
BiondVax's CEO, commented, "This financing, together with the
€20 million EIB funding, the Israeli Government support, and our
other existing resources enables us to launch our Phase 3 program
including a mid-size manufacturing facility."
Joseph Gunnar & Co., LLC is
acting as the sole book-running manager for the offering.
The ADSs described above will be issued pursuant to a
registration statement on Form F-3 previously filed with and
subsequently declared effective by the Securities and Exchange
Commission (SEC) on December 15,
2016. The securities may be offered only by means of a
prospectus and related prospectus supplement. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering has been filed with the SEC and will be available on the
SEC's website at http://www.sec.gov.
Before buying any of BiondVax's ADSs in the offering, investors
should carefully read the preliminary prospectus supplement and the
accompanying prospectus, together with the information incorporated
by reference therein. These documents contain important information
that investors should consider when making their investment
decisions. Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these ADSs may be obtained by
contacting Joseph Gunnar & Co.,
LLC, Prospectus Department, 30 Broad Street, 11th Floor,
New York, NY 10004, telephone
212-440-9600, email: prospectus@jgunnar.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such
jurisdiction.
About BiondVax
BiondVax is a biopharmaceutical
company developing M-001, a universal flu vaccine candidate
approaching Phase 3 clinical trials. The vaccine is designed to
provide multi-season protection against most seasonal and pandemic
human influenza virus strains. BiondVax's proprietary technology
utilizes a unique combination of conserved and common peptides from
influenza virus proteins, activating both arms of the immune system
for a cross-protecting and long-lasting effect. BiondVax is traded
on NASDAQ: BVXV and TASE: BVXV. For more information, please
visit www.biondvax.com.
Contact Details
Joshua
Phillipson
Business Development
+972-8-930-2529
j.phillipson@biondvax.com
Forward Looking Statements
This press release
contains forward-looking statements within the meaning of the
Private Litigation Reform Act of 1995. Words such as "expect,"
"believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve certain risks and uncertainties reflect the management's
current views with respect to certain current and future events and
are subject to various risks, uncertainties and assumptions that
could cause the results to differ materially from those expected by
the management of BiondVax Pharmaceuticals Ltd. risks and
uncertainties include, but are not limited to, the risk that drug
development involves a lengthy and expensive process with uncertain
outcome, the results of the contemplated Phase 2 & 3
trials, delays or obstacles in launching and/or
successfully completing our clinical trials, the
impact of the global economic environment on the Company customer
target base, the adequacy of available cash resource and the
ability to raise capital when needed. More
detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2016 filed with the U.S. Securities
and Exchange Commission, or SEC, which is available on the SEC's
website, www.sec.gov, and in the Company's
periodic filings with the SEC and the Tel-Aviv Stock
Exchange.
View original
content:http://www.prnewswire.com/news-releases/biondvax-announces-pricing-of-public-offering-of-american-depositary-shares-300519353.html
SOURCE BiondVax Pharmaceuticals Ltd.